Evidence based treatment of heart failure;Tratamiento médico de la insuficiencia cardíaca basado en la evidencia

Revista Espanola de Cardiologia

Volumn 54, Issue 6, 2001, Pages 715-734

  Agustí Escasany, Antònia ^a   Durán Dalmau, Marta ^a   Arnau De Bolós, Josep Ma ^a   Rodríguez Cumplido, Dolores ^a   Diogène Fadini, Eduard ^a   Casas Rodríguez, José ^b   Galve Basilio, Enrique ^a   Manito Lorite, Nicolás ^c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b ABS Raval Sud   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Beta blockers; Conversive enzyme inhibitors; Diuretics; Heart failure

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FUROSEMIDE; HYDRALAZINE; IBOPAMINE; IONOTROPIC RECEPTOR AGONIST; ISOSORBIDE DINITRATE; LOSARTAN; METOPROLOL; MILRINONE; NIFEDIPINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT; VERAPAMIL; XAMOTEROL;

ARTICLE; CLINICAL TRIAL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART FUNCTION; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; QUALITY OF LIFE; SYMPTOMATOLOGY;

EID: 0343337170     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(01)76387-7     Document Type: Article

References (187)

1. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC et al. The epidemiology of heart failure. Eur Heart J 1997; 18: 208-225.
2. Cowie MR, Wood DA, Coats AJS, Thompson SG, Poole-Wilson PA, Suresh V et al. Incidence and aetiology of heart failure. A population-based study. Eur Heart J 1999; 20: 421-428
3. Davis RC, Hobbs FDR, Lip GYH. ABC of Heart Failure. History and epidemiology. Br Med J 2000; 320: 39-42.
4. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-115.
5. Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiophatic dilated cardiomyopathy. Am J Cardiol 1983; 51: 831-836.
6. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR et al. Congestive heart failure in the community. Trends in incidence and survival in a 10-year period. Arch Intern Med 1999; 159: 29-34.
7. Sharpe N, Doushty R. Epidemiology of heart failure and ventricular dysfunction. Lancet 1998; 352 (Supl I): 3-7.
8. Rodríguez-Artalejo F, Guallar-Castillón P, Banegas Banegas JR, Del Rey Calero J. Variación geográfica en las hospitalizaciones y en la mortalidad por insuficiencia cardíaca congestiva en España, 1980-1993. Rev Esp Cardiol 2000; 53: 776-782.
9. The Large State Peer Review Organization Consortium. Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare pacients in 10 large states. Arch Intern Med 1997; 157: 1103-1108.
10. Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997; 157: 2460-2464.
11. Bello D, Shah NB, Edep ME, Tateo IM, Massie BM. Self-reported differences bertween cardiologists and heart failure specialists in the management of chronic heart failure. Am Heart J 1999; 138: 100-107.
12. Edep ME, Shah NB, Tateo IM, Massie BM. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 1997; 30: 518-526.
13. Van Veldhuisen DJ, Charlesworth A, Crijns HJGM, Lie KI, Hampton JR. Differences in drug treatment of chronic heart failure between European countries. Eur Heart J 1999; 20: 666-672.
14. Konstam M, Dracup K, Baker D. Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction. Clinical practice guidelines N.o 11. Agency for Health Care Policy and Research Publication N.o 94-0612. Public Health Service, EE.UU, 1994.
15. Navarro-López, F, De Teresa E, López-Sendón JL, Castro-Beiras A. Guías del diagnóstico, clasificación y tratamiento de la insuficiencia cardíaca y del shock cadiogénico. Informe del Grupo de Trabajo de Insuficiencia Cardíaca de la Sociedad Española de Cardiología. Rev Esp Cardiol 1999; 52 (Supl 2): 1-54.
16. The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997; 18: 736-753.
17. ACC/AHA Task Force Report. Guidelines for the evaluation and management of heart failure. Circulation 1995; 92: 2764-2784.
18. Jovell AJ, Navarro-Rubio MD, Aymerich M, Serra-Prat M. Metodología de diseño y elaboración de guías de práctica clínica en atención primaria. Aten Primaria 1997; 20: 259-266.
19. Jovell AJ, Navarro MD. Guías de práctica clínica. FMC Aten Primaria 1995; 2: 152-156.
20. Eddy DM. Guidelines for policy statements: the explicit approach. JAMA 1990; 263: 2239-2243.
21. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-1456.
22. Eccles M, Freemantle N, Mason J for the North of England ACE-inhibitor Guideline Development Group. North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symtomatic heart failure. Br Med J 1998; 316: 1369-1375.
23. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymtomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327: 685-691.
24. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
25. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, for the ACE-Inhibitor Myocardial Infarction Collaborative. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individuals patients. Lancet 2000; 355: 1575-1581.
26. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-1435.
27. Beller B, Bulle T, Bourge RC, Colfer H, Fowles RE, Giles TD et al. Lisinopril versus placebo in the treatment of heart failure. J Clin Pharmacol 1995; 35: 673-680.
28. Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Fur Heart J 1995; 16: 1892-1899.
29. Chalmers JP, West MJ, Cyran J, De la Torre D, Englert M, Kramar M et al. Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study. J Cardiovasc Pharmacol 1987; 9 (Supl 3): 89-97.
30. Anónimo. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983; 2: 755-763.
31. Brown EJ, Chew PH, MacLean A, Gelperin K, Ilgenfritz JP, Blumenthal M. Effects of fosinopril on tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Am J Cardiol 1995; 75: 596-600.
32. Circo A, Platania F, Mangiameli S, Putignano E. Multicenter, randomised, placebo-controlled, double-blind study of the safety and efficacy of oral delapril in patients with congestive heart failure. Am J Cardiol 1995; 75 (Supl F); 18-24.
33. Northridge DB, Rose E, Raftery DE, Lahiri A, Elder AT, Shaw TR et al. A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure. Eur Heart J 1993; 14: 403-409.
34. Colfer HT, Ribner HS, Gradman A, Hughes CV, Kapoor A, Laidlaw JC. Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. The benazepril Heart Failure Study Group. Am J Cardiol 1992; 70: 354-358.
35. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic heart failure. N Engl J Med 1991; 325: 303-310.
36. Lechat P, Garnham SP, Desche P, Bounhoure JP. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. Am Heart J 1993; 126: 798-806.
37. Bounhoure JP, Bottineau G, Lechat P, Garnham J, Lapeyre G. Value of perindopril in the treatment of chronic congestive heart failure. Clin Exp Hypertens 1989; 11 (Supl 2): 575-586.
38. Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. J Am Coll Cardiol 1993; 22: 1557-1563.
39. Sharpe DN, Murphy J, Coxon R, Hannan SF. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation 1984; 70: 271-278.
40. Barabino A, Galbariggi G, Pizzorni C, Lotti G. Comparative effects of long-term therapy with captopril and ibopamine in chronic congestive heart failure in old patients. Cardiology 1991; 78: 289-296.
41. Widimsky J, Kremer HJ, Jerie P, Uhlir O, for the CASIS investigators. Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure. Eur J Clin Pharmacol 1995; 49: 95-102.
42. Magnani B, Magelli C, for The Multicenter Research Groups on Mild Heart Failure: preliminary observations of a long-term double-blind, placebo-controlled trial. Postgrad Med J 1986; 62 (Supl 1): 153-158.
43. Drexler H, Banhardt BS, Meinertz T, Wollschlager H, Lehmann M, Just H. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure: a double-blind, placebo controlled trial. Circulation 1989; 79: 491-502.
44. Dickstein K, Barvik S, Aarsland T. Effect of long-term enalapril therapy on cardiopulmonary exercise performance in men with mild heart failure and previous myocardial infarction. J Am Coll Cardiol 1991; 18: 596-602.
45. Cleland JGF, Dargie HJ, Ball SG, Gillen G, Hodsman GP, Morton JJ et al. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985; 54: 305-311.
46. Riegger GAJ. Effects of quinapril on exercice tolerance in patients with mild to moderate heart failure. Eur Heart J 1991; 12: 705-711.
47. Gundersen T, Swedberg K, Amtorp O, Remes J, Nilsson B. Absense of effect on exercise capacity of 12-weeks treatment with ramipril in patients moderate congestive heart failure. Eur Heart J 1994; 15: 1659-1665.
48. Dössegger L, Aldor E, Baird MG, Braun S, Cleland JG, Donaldson R et al. Influence of angiotensin converting enzyme inhibition on exercice perfomance and clinical symptoms in chronic heart failure: a multicentre. double-blind, placebo-controlled trial. Eur Heart J 1993; 14 (Supl C): 18-23.
49. Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM et al. Adverse effects of enalapril in the Studies of Left Ventricular dysfunction. Am Heart J 1996; 131: 350-355.
50. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Affect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-827.
51. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE et al, on Behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-677.
52. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K et al, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-1676.
53. The Network Investigators. Clinical outcome with enalapril in symtomatic chronic heart failure; a dose comparison. Eur Heart J 1998; 19: 481-489.
54. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM et al, on behalf of the ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-2318.
55. Pitt B, Poole-Wilson PA, Segal R, Martínez FA, Dickstein K, Camm AJ, on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randimised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
56. Pitt B, Segal R, Martinez, FA, Meurers G, Cowley AJ, Thomas I et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
57. Nordrehaug JE, Omsj IH, Vollset SE. A 3-month double-blind cross-over study of the effect of benazepril and hydrochlorothiazide on functional class in symptomatic mild heart failure. J Intern Med 1992; 231: 589-594.
58. Richardson A, Scriven AJ, Poole-Wilson PA, Bayliss J, Parameshwar J, Sutton GC. Double-blind comparison of captopril alone against furosemide plus amiloride in mild heart failure. Lancet 1987; 2: 709-711.
59. Boccanelli A, Zachara E, Liberatore SM, Carboni GP, Prati PL. Addition of captopril versus increasing diuretics in moderate but deteriorating heart failure: a double-blind comparative trial. Postgrad Med J 1986; 62 (Supl 1): 184-187.
60. Cowley AJ, Stainer K, Wynne RD, Rowley JM, Hampton JR. Symptomatic assessment of patients with heart failure: double-blind comparison of increasing doses of diuretics and captopril in moderate heart failure. Lancet 1986; 2: 770-772.
61. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild or moderate heart failure. JAMA 1988; 259: 539-544.
62. Beaune J. Comparison of enalapril versus digoxin for congestive heart failure. Am J Cardiol 1989; 63 (Supl D): 22-25.
63. Davies RF, Beanlands DS, Nadeau C, Phaneuf D, Morris A, Arnold JM et al. Enalapril versus digoxin in patients wilh congestive heart failure: a multicenter study. Canadian Enalapril Versus Digoxin Study Group. J Am Coll Cardiol 1991; 18: 1602-1609.
64. Kloleif MA, Pringle S, Kesson E, Murray G, Kennedy JA, Lorimer AR et al. A comparison of the efficacy and safety of ramipril and digoxin added to maintenance diuretic treatment in patients with chronic heart failure. J Cardiovascular Pharmacol 1991; 18 (Supl 2): 180-183.
65. Dickstein K, Chang P, Willenheimer R, Hauns S, Remes J, Hall C et al. Comparison of the effects of losartan and enalapril on clinical status and exercice performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995; 26: 438-445.
66. Lang RM, Elkayam U, Yellen LG, Krauss D, McKelvie RS, Vaughan DE et al. Comparative effects of losartan and enalapril on exercice capacity and clinical status in patients with heart failure. J Am Coll Cardiol 1997; 30: 983-991.
67. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987; 57: 17-22.
68. Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol 1994; 73: 881-886.
69. Walma EP, Hoes AW, Van der Does E. Withdrawal of long-term diuretic medication in elderly patients: a double bllind randomised trial. Br Med J 1997; 315: 464-468.
70. Cowley AJ, Stainer K, Wynne RD, Rowley JM, Hampton JR. Symptomatic assessment of patients with heart failure: double-blind comparison of increasing doses of diuretics and captopril in moderate heart failure. Lancet 1986; 2: 770-772.
71. Richardson A, Scriven AJ, Poole-Wilson PA, Bayliss J, Parameshwar J, Sutton GC. Double-blind comparison of captopril alone against furosemide plus amiloride in mild heart failure. Lancet 1987; 2: 709-711.
72. Channer KS, McLean KA, Lawson Matthew P, Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 1994; 71: 146-150.
73. Dormans TP, Gerlag PG. Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J 1996; 17: 1867-1874.
74. Kiyingi A, Field MJ, Pawsey CC, Yiannikas J, Lawrence JR. Arter WJ. Metolazone in treatment of severe refractory congestive cardiac failure. Lancet 1990; 335: 29-31.
75. Van Vliet AA, Donker JM, Nauta JJP, Verheugt FWA. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor Am J Cardiol 1993; 71 (Supl A): 21-28.
76. Dahlström U, Karlsson E. Captopril and spironolactone therapy for refractory congestive heart failure. Am J Cardiol 1993; 71 (Supl A): 29-33.
77. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 76: 1259-1265.
78. Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993; 71 (Supl A): 3-11.
79. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the rennin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63: 645-651.
80. Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a parcial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993; 33: 40-45.
81. Staessen J, Lijren P, Fagard R, Vetschucren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angioiensin II suppression. J Endocrinol 1981; 91: 457-465.
82. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78: 902-907.
83. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al, for The Randomised Aldactone Elaluation Study Investigators. The effect of spironolactone en morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
84. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
85. Dargie HJ, McMurray JJV. Diagnosis and management of heart failure. Br Med J 1994; 308: 321-328.
86. Jaeschke R, Oxman AD, Guyatt GH. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview aid meta-analysis. Am J Med 1990; 80: 279-286.
87. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993; 22: 955-962.
88. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993; 329: 1-7.
89. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989; 320: 677-683.
90. Fleg JL, Rothteld B, Gottlieb SH. Effect of maintenance digoxin therapy on acrobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease: a randomised, placebo-controlled, crossover trial. J Am Coll Cardiol 1991; 17: 743-751.
91. Van Veldhuisen DJ, Man in't Veld AJ, Duselman PH, Lok DJ, Dohmen HJ, Poortermans JC et al. Double-blind placebo-controlled sludy of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch ibopamine multicenter Trial (DIMT). J Am Coll Cardiol 1993; 22: 1564-1573.
92. The German And Australian Xamoterol Study Group. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet 1988; 1: 489-1493.
93. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J 1997; 18: 560-565.
94. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997; 30: 27-34.
95. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of β-adrenergic blockade in chronic heart failure. Circulation 1998; 98: 1184-1191.
96. Bonet S, Agustí A, Arnau JM, Vidal X, Diogène E, Galve E et al. β-adrenergic blocking agents in heart failure. Benefits of vasodilating and nonvasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med 2000; 160: 621-627.
97. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
98. Anónimo. Beta-blockers under-used un heart failure. COPER-NICUS data in full. Scrip 2000; 2572: 20.
99. Anónimo. Population basis for bucindolol failure? Scrip 1999; 2491: 20.
100. Bristow MR. β-adrenergic receptor blokade in chronic heart failure. Circulation 2000; 101: 558-569.
101. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. β-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371.
102. β-Blocker Heart Attack Study Trial. The β-Blocker Heart Attack Trial. JAMA 1981; 246: 2073-2074.
103. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-807.
104. Hjalmarson A, Elmfeldt D, Herlitz I, Holmberg S, Málek I, Nyberg G et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981; 2: 823-827.
105. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-497.
106. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 1999; 318: 1730-1737.
107. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE et al, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-2816.
108. Cohn JN, Fowler MB, Bristow MA, Colucci WS, Gilbert EM, Kinal V et al. Effect of carvedilol in severe chronic heart failure. J Am Coll Cardiol 1996; 27 (Supl A): 169.
109. Olsen SL, Gilbert EM, Renlud DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double blind randomized study. J Am Coll Cardiol 1995; 25: 1225-1231.
110. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I et al, for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Circulation 1996; 94: 2793-2799.
111. Paolisso G, Gambardella A, Marrazzo G, Verza M, Teasuro P, Varricchio M et al. Metabolic and cardiovascular benefits deriving from α-adrenergic blockade in chronic congestive heart failure. Am Heart J 1992; 123: 103-110.
112. Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990; 66: 603-607.
113. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG et al. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990; 88: 223-229.
114. Colucci W, Packer M, Bristow MR, Gilbert M, Cohn JN, Fowler MB et al for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800-2806.
115. Currie PJ, Kelly MJ, McKenzie A, Harper RW, Lim YL, Federman J et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol 1984; 3: 203-209.
116. Ikram H, Fitzpatrick D. Double blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet 1981; 2: 490-493.
117. Anderson JL, Lutz JR, Gilbert EM, Sorensen SG, Yanowitz FG, Menlove RL et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985; 55: 471-475.
118. Sanderson JE, Chan SK, Yu CM, Yeung LY, Chan WM, Raymond K et al. β blockers in heart failure: a comparison of a vasodilating β blocker with metoprolol. Heart 1998; 79: 86-92.
119. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA et al, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-1446.
120. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985; 72: 536-546.
121. Fisher ML, Gottlieb SS, Plotnik GD, Geenberg NL, Patten RD, Bennett SK et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomised trial. J Am Coll Cardiol 1994; 23: 943-950.
122. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995; 92: 1499-1506.
123. Metra M, Nardi M, Raccagni D, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994; 24: 1678-1687.
124. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz EN et al for the Bucindolol Investigators. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994; 89: 1632-1642.
125. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, for the MERIT-HF Study Group. Effects of controlled - release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000; 283: 1295-1302.
126. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
127. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al for The US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbility and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355.
128. Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercice, ejection fraction, and oxidative stress in heart failure. Circulation 1999; 99: 2645-2651.
129. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of the Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547-1552.
130. The Multicenter Postinfarction Resarch Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309: 331-336.
131. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol 1990; 66: 779-785.
132. Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E, for the SPRINT Study Group. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993; 153: 345-353.
133. Packer M, O'Connor CM, Ghali JK, Pressler M, Carson PE, Belkin RN, for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-1114.
134. Anónimo. Norvasc disappoints in heart failure. Scrip 2000; 2524: 22.
135. Cohn JN, Ziesche S, Smith R, Anand I, Dinkman B, Loeb H, for the Vasodilator-Heart Failure Trial (V-Heft) Study Group. Effect of the calcium antagonists felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril V-HeFT III. Circulation 1997; 96: 856-863.
136. Agostini P, Doria E, Riva S. Polese A. Acute and chronic efficacy of felodipine in congestive heart failure. Int J Cardiol 1991; 30: 89-95.
137. Dunselman PHJM, Kuntze CEE, van Bruggen A, Hamer JPM, Scaf AHJ, Wesseling H et al. Efficacy of felodipine in congestive heart failure. Eur Heart J 1989; 10: 354-364.
138. Rovere MT, Mortara A, Opasich C, Specchia G. Acute and chronic effects of nicardipine on rest and exercise haemodynamics in post-myocardial infarction patients with latent cardiac failure. Eur Heart J 1989; 10: 429-436.
139. Tan LB, Murray RG, Litter WA. Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects. Br Heart J 1987; 58: 122-128.
140. Litter WA, Sheridan DJ, on behalf of the UK Study Group. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. Br Heart J 1995; 73: 428-433.
141. Walsh JT, Andrews R, Curtis S, Evans A, Cowley AJ. Effects of amlodipine in patients with chronic heart failure. Am Heart J 1997; 134: 872-878.
142. Wout van den Toren E, Van Veldhuisen DJ, Van Bruggen A, Van den Broek SAJ, Van Gilst WH, Lie KI. Acute hemodynamic and long-term clinical effects of isradipine in patients with coronary artery disease and chronic heart failure. A double-blind, placebo-controlled study. Int J Cardiol 1996; 53: 37-43.
143. Lewis BS, Makhoul N, Merdler A, Flugelman MY, Front A, Hardoff R et al. Effect of nisoldipine on exercise performance in heart failure following myocardial infarction. Cardiology 1991; 79: 39-45.
144. The DEFIANT-II Research Group. Doppler flow and achocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Results of the DEFIANT-II study. Eur Heart J 1997; 18: 31-40.
145. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990; 336: 1-6.
146. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468-1475.
147. Hampton JR, Van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, for the Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997; 349: 971-977.
148. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, for the Vesnarinone Study Group. Effects of vesnarinone on mortality in patients with heart failure. N Engl J Med 1993; 329; 149-155.
149. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, for the Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998; 339: 1810-1816.
150. Vigholt-Sorensen E, Faergeman O. Ischaemic left ventricular failure: evidence of sustained benefit after 18 months' treatment with xamoterol. Br Heart J 1990; 64: 186-189.
151. Leier CV, Dalpiaz K, Huss P, Hermiller JB, Magorien RD, Bashore TM et al. Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. Am J Cardiol 1993; 52: 304-308.
152. Dibianco R, Shabetai R, Silverman BD, Leier CV, Benotti JR, with the amrinone multicenter study investigators. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol 1984; 4: 855-866.
153. Amiodarone Trials Meta-analysis Investigators. Effect of prophylactic a niodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350: 1417-1424.
154. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R, for Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low -dose amiodarone in severe congestive heart
155. Singh SN, Fletcher RD, Gross Fischer S, Singh BN, Lewis HD, Deedwania PC et al, for The Survival Trial of Antiarrhythmic Therapy in congestive Heart Failure. Amiodarone in patients with congestive heart failure and asymtomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77-82.
156. Elizari MV, Martínez JM, Belziti C, Ciruzzi M, Pérez de la Hoz R, Sinisi A et al. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. GEMICA study investigators, GEMA Group, Buenos Aires, Argentina. Grupo de Eistudios Multicéntricos en Argentina. Eur Heart J 2000; 21: 198-205.
157. Julian DG, Camm AJ, Frangin G, Janse MJ, Muñoz A, Schwartz PJ et al, for the European Myocardial Infarct Amiodarone Trial Investigators. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-674.
158. Cairns JA, Connolly SJ, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997; 349: 675-682.
159. Moss AJ, Hall J, Cannon DS, Daubert JP, Higgins SL, Klein H et al, for the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillation in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-1940.
160. Massie BM, Fisher SG, Deedmania PC, Singh NBN, Fletcher RD, Singh SN. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHT-STAT investigators. Circulation 1996; 93: 2128-2134.
161. Hamer AWF, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J Am Coll Cardiol 1989; 14: 1768-1774.
162. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for the prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989; 1: 175-179.
163. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991; 84: 527-539.
164. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511.
165. Connolly S, Laupacis A, Gent M, Roberts R, Cairns J, Joyner C, fot the CAFA Study coinvestigators. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-355.
166. The Veterans Affairs Stroke Prevention in Non-rheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation (SPINAF). N Engl J Med 1992; 327: 1406-1412.
167. Loh E, Sutton MS, Wun CC, Rouleau JI, Flaker GC, Gottlieb SS et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336: 251-257.
168. Cioffi G, Pozzoli M, Forni M, Franchini M, Opasich C, Cobelli F, Tavazzi L with the technical assistance of D. Rossi. Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. Eur Heart J 1996; 17: 1381-1389.
169. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Branderburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-531.
170. Katz SD, Marantz PR, Biasucci L, Jondeau G, Lee K, Brennan C et al. Low incidence of stroke in patients with heart failure: a prospective study. Am Heart J 1993; 126: 141-146.
171. Natterson PD, Stevenson WG, Saxon LA, Middlekauff HR, Stevenson LW. Risk of arterial embolization in 224 patients awaiting cardiac transplantation. Am Heart J 1995; 129: 564-570.
172. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. The V-HeFT Cooperative Studies Group. Circulation 1993; 87 (Supl VI): 94-101.
173. Al Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstant MA. Warfarin anticoagulalion and survival: a cohort analysis from the studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 31: 749-753.
174. Tsevat J, Eckman M, McNutt R, Pauker SG. Warfarin for dilated cardiomyopathy: a bloody tough pill to swallow? Med Decis Making 1989; 9: 162-169.
175. Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice. The case of heart failure. Arch Intern Med 1999; 159: 1690-1700.
176. Paul SD, Kuntz KM, Eagle KA, Weinstein MC. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994; 154: 1143-1149.
177. Butler JRG, Fletcher PJ. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. Aust N Z J Med 1996; 26: 89-95.
178. Kleber FX. Socioeconomic aspects of ACE inhibition in the secondary prevention in cardiovascular diseases. Am J Hypertens 1994; 7 (Supl 1): 112-116.
179. Tsevat J, Duke D, Goldman L, Pfeffer MA, Lamas GA, Soukup JR et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995; 26: 914-919.
180. Michel BC, Remme WJ, Kingman JH, Kragten JA, Van Nieuwenhuizen R, Van Hout BA. Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in the Netherlands. Eur Heart J 1996; 17: 731-740.
181. Antoñanzas F, Antón F, Echevarría L. Análisis coste efectividad del tratamiento con enalapril de la insuficiencia cardíaca crónica en Fspaña. Gac Sanit 1996; 10: 135-142.
182. Ward RF, Gheorghiade M, Young JB, Uretsky B. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. J Am Coll Cardiol 1995; 26: 93-101.
183. Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G. Cost-efectiveness of carvedilol for heart failure. Am J Cardiol 1999; 83: 890-896.
184. Woolf SH. Practice guidelines - a new reality in medicine: II: methods of developing guidelines. Arch Intern Med 1992; 152: 946-952.
185. Grimshaw J, Eccles M, Russell I. Developing clinically valid practice guidelines. J Evaluation Clin Prac 1995; 1: 37-48.
186. Grimshaw J, Russell I. Achieving health gain through clinical guidelines. I: developing scientifically valid guidelines. Quality Health Care 1993; 2: 243-248.
187. Jovell AJ, Navarro-Rubio MD. Evaluación de la evidencia científica. Med Clin (Barc) 1995; 105: 740-743.